Matrix stiffness in tumor immune evasion and immunotherapy resistance: from mechanotransduction to therapeutic intervention
- 1Clinical Research Center, Xianyang Central Hospital, Xianyang, Shaanxi, China
- 2Department of Thoracic Surgery, Air Force Hospital of Southern Theater Command, Guangzhou, Guangdong, China
Abstract
The tumor microenvironment is characterized not only by biochemical alterations but also by profound biophysical abnormalities, among which increased extracellular matrix (ECM) stiffness represents a defining hallmark of solid malignancies. Once regarded as a passive structural consequence of desmoplasia, matrix stiffness is now recognized as an active, master regulator of anti-tumor immunity. This review synthesizes current understanding of how elevated matrix stiffness orchestrates immune suppression through interconnected biophysical and biochemical mechanisms. We delineate the biophysical basis of tumor stiffening driven by enhanced collagen deposition, lysyl oxidase-mediated crosslinking, and cancer-associated fibroblast activation. We systematically examine how stiff matrices reshape innate immunity, emphasizing that macrophage polarization is context-dependent: M2-like immunosuppressive phenotypes predominate in the stiff tumor stroma, whereas defined biomaterial substrates can prime inflammatory states. We also cover the metabolic reprogramming of tumor-associated macrophages that depletes arginine while secreting immunosuppressive ornithine, as well as altered dendritic cell maturation and function. We then discuss how stiff matrices suppress adaptive immunity by physically impeding T lymphocyte migration, actively inducing CD8+ T cell terminal exhaustion through the recently discovered Piezo1/Ca²+/CaMKII/CREB/Osr2 biomechanical checkpoint, promoting regulatory T cell (Treg) differentiation, and upregulating immune checkpoint ligands including PD-L1 and PD-L2. We further discuss mechanotransduction signaling cascades that translate physical cues into immunological outcomes, and evaluate emerging therapeutic strategies to normalize matrix stiffness (including ECM-targeting agents, mechanosignaling inhibitors, and mechano-optimized cellular therapies) and their synergistic combination with immune checkpoint blockade. We conclude by highlighting key challenges and future directions for translating mechano-immunological insights into clinical practice.
Related
- Extracellular matrix stiffness determines the phenotypic behavior of dedifferentiated melanoma cells through a DDR1/2-dependent YAP mechanotransduction pathway
- Matrix‑stiffness‑triggered mechanotransduction fuels hepatocellular carcinoma proliferation through Hippo‑orchestrated ANKRD1‑PRMT5 complex‑driven arginine methylome remodeling
- Hydrogel-based reprogramming of the tumor inflammatory microenvironment: from mechanotransduction and dynamic materials to adaptive immunotherapy
- Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting
- Editorial: The differentiation and reprogramming of tumor-associated myeloid cells and therapeutic strategies for cancer immunotherapy
BibTeX
@article{guo2026matrix,
title = {{Matrix stiffness in tumor immune evasion and immunotherapy resistance: from mechanotransduction to therapeutic intervention}},
author = {Wenwen Guo and Tianyun Qiao},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1935194},
url = {https://doi.org/10.3389/fimmu.2026.1935194},
note = {CC BY},
}
RIS
TY - JOUR
TI - Matrix stiffness in tumor immune evasion and immunotherapy resistance: from mechanotransduction to therapeutic intervention
AU - Wenwen Guo
AU - Tianyun Qiao
PY - 2026
DA - 2026/11/09
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1935194
UR - https://doi.org/10.3389/fimmu.2026.1935194
AB - The tumor microenvironment is characterized not only by biochemical alterations but also by profound biophysical abnormalities, among which increased extracellular matrix (ECM) stiffness represents a defining hallmark of solid malignancies. Once regarded as a passive structural consequence of desmoplasia, matrix stiffness is now recognized as an active, master regulator of anti-tumor immunity. This review synthesizes current understanding of how elevated matrix stiffness orchestrates immune suppression through interconnected biophysical and biochemical mechanisms. We delineate the biophysical basis of tumor stiffening driven by enhanced collagen deposition, lysyl oxidase-mediated crosslinking, and cancer-associated fibroblast activation. We systematically examine how stiff matrices reshape innate immunity, emphasizing that macrophage polarization is context-dependent: M2-like immunosuppressive phenotypes predominate in the stiff tumor stroma, whereas defined biomaterial substrates can prime inflammatory states. We also cover the metabolic reprogramming of tumor-associated macrophages that depletes arginine while secreting immunosuppressive ornithine, as well as altered dendritic cell maturation and function. We then discuss how stiff matrices suppress adaptive immunity by physically impeding T lymphocyte migration, actively inducing CD8+ T cell terminal exhaustion through the recently discovered Piezo1/Ca²+/CaMKII/CREB/Osr2 biomechanical checkpoint, promoting regulatory T cell (Treg) differentiation, and upregulating immune checkpoint ligands including PD-L1 and PD-L2. We further discuss mechanotransduction signaling cascades that translate physical cues into immunological outcomes, and evaluate emerging therapeutic strategies to normalize matrix stiffness (including ECM-targeting agents, mechanosignaling inhibitors, and mechano-optimized cellular therapies) and their synergistic combination with immune checkpoint blockade. We conclude by highlighting key challenges and future directions for translating mechano-immunological insights into clinical practice.
SN - 1664-3224
ER -